APO Research
Talk to an analyst

APO RESEARCH · REPORT

AT1 Receptor Antagonists

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global AT1 Receptor Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025197 pages

Choose your research edition.

Industry ResearchAT1 Receptor Antagonists Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal AT1 Receptor Antagonists Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal AT1 Receptor Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal AT1 Receptor Antagonists Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal AT1 Receptor Antagonists Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global AT1 Receptor Antagonists market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for AT1 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for AT1 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for AT1 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for AT1 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of AT1 Receptor Antagonists include Teva Pharmaceutical, Sanofi, Jhonson and Johnson, Novartis, Merck, Eli Lilly, Pfizer, GSK and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global AT1 Receptor Antagonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of AT1 Receptor Antagonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents AT1 Receptor Antagonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the AT1 Receptor Antagonists market size, projected growth trends, production technologies, key applications, and end-use industries.

AT1 Receptor Antagonists Segment by Company

Teva Pharmaceutical

Sanofi

Jhonson and Johnson

Novartis

Merck

Eli Lilly

Pfizer

GSK

Bayer

Bristol-Myers Squibb

Astra Zeneca

AT1 Receptor Antagonists Segment by Type

Valsartan

Telmisartan

Losartan

Irbesartan

Olmesartan

Azilsartan

AT1 Receptor Antagonists Segment by Application

Cardiovascular Diseases

Kidney Diseases

Hypertension

Other

AT1 Receptor Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AT1 Receptor Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of AT1 Receptor Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AT1 Receptor Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the AT1 Receptor Antagonists market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of AT1 Receptor Antagonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of AT1 Receptor Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of AT1 Receptor Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. AT1 Receptor Antagonists Industry Trends Table 2. AT1 Receptor Antagonists Industry Drivers Table 3. AT1 Receptor Antagonists Industry Opportunities and Challenges Table 4. AT1 Receptor Antagonists Industry Restraints Table 5. Global AT1 Receptor Antagonists Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global AT1 Receptor Antagonists Revenue Market Share by Manufacturers (2021-2026) Table 7. Global AT1 Receptor Antagonists Sales by Manufacturers (k tons) & (2021-2026) Table 8. Global AT1 Receptor Antagonists Sales Market Share by Manufacturers Table 9. Global AT1 Receptor Antagonists Average Sales Price (US$/ton) of Manufacturers (2021-2026) Table 10. Global AT1 Receptor Antagonists Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global AT1 Receptor Antagonists Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global AT1 Receptor Antagonists Manufacturers, Product Type & Application Table 13. Global AT1 Receptor Antagonists Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global AT1 Receptor Antagonists by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Valsartan Table 17. Major Manufacturers of Telmisartan Table 18. Major Manufacturers of Losartan Table 19. Major Manufacturers of Irbesartan Table 20. Major Manufacturers of Olmesartan Table 21. Major Manufacturers of Azilsartan Table 22. Global AT1 Receptor Antagonists Sales by Type 2021 VS 2025 VS 2032 (k tons) Table 23. Global AT1 Receptor Antagonists Sales by Type (2021-2026) & (k tons) Table 24. Global AT1 Receptor Antagonists Sales by Type (2027-2032) & (k tons) Table 25. Global AT1 Receptor Antagonists Sales Market Share by Type (2021-2026) Table 26. Global AT1 Receptor Antagonists Sales Market Share by Type (2027-2032) Table 27. Global AT1 Receptor Antagonists Revenue by Type 2021 VS 2025 VS 2032 (k tons) Table 28. Global AT1 Receptor Antagonists Revenue by Type (2021-2026) & (k tons) Table 29. Global AT1 Receptor Antagonists Revenue by Type (2027-2032) & (k tons) Table 30. Global AT1 Receptor Antagonists Revenue Market Share by Type (2021-2026) Table 31. Global AT1 Receptor Antagonists Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Cardiovascular Diseases Table 33. Major Manufacturers of Kidney Diseases Table 34. Major Manufacturers of Hypertension Table 35. Major Manufacturers of Other Table 36. Global AT1 Receptor Antagonists Sales by Application 2021 VS 2025 VS 2032 (k tons) Table 37. Global AT1 Receptor Antagonists Sales by Application (2021-2026) & (k tons) Table 38. Global AT1 Receptor Antagonists Sales by Application (2027-2032) & (k tons) Table 39. Global AT1 Receptor Antagonists Sales Market Share by Application (2021-2026) Table 40. Global AT1 Receptor Antagonists Sales Market Share by Application (2027-2032) Table 41. Global AT1 Receptor Antagonists Revenue by Application 2021 VS 2025 VS 2032 (k tons) Table 42. Global AT1 Receptor Antagonists Revenue by Application (2021-2026) & (k tons) Table 43. Global AT1 Receptor Antagonists Revenue by Application (2027-2032) & (k tons) Table 44. Global AT1 Receptor Antagonists Revenue Market Share by Application (2021-2026) Table 45. Global AT1 Receptor Antagonists Revenue Market Share by Application (2027-2032) Table 46. Global AT1 Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 47. Global AT1 Receptor Antagonists Sales by Region (2021-2026) & (k tons) Table 48. Global AT1 Receptor Antagonists Sales Market Share by Region (2021-2026) Table 49. Global AT1 Receptor Antagonists Sales Forecasted by Region (2027-2032) & (k tons) Table 50. Global AT1 Receptor Antagonists Sales Forecasted Market Share by Region (2027-2032) Table 51. North America AT1 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 52. North America AT1 Receptor Antagonists Sales by Country (2021-2026) & (k tons) Table 53. North America AT1 Receptor Antagonists Sales by Country (2027-2032) & (k tons) Table 54. Europe AT1 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 55. Europe AT1 Receptor Antagonists Sales by Country (2021-2026) & (k tons) Table 56. Europe AT1 Receptor Antagonists Sales by Country (2027-2032) & (k tons) Table 57. Asia Pacific AT1 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 58. Asia Pacific AT1 Receptor Antagonists Sales by Country (2021-2026) & (k tons) Table 59. Asia Pacific AT1 Receptor Antagonists Sales by Country (2027-2032) & (k tons) Table 60. South America, Middle East and Africa AT1 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 61. South America, Middle East and Africa AT1 Receptor Antagonists Sales by Country (2021-2026) & (k tons) Table 62. South America, Middle East and Africa AT1 Receptor Antagonists Sales by Country (2027-2032) & (k tons) Table 63. Global AT1 Receptor Antagonists Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global AT1 Receptor Antagonists Revenue by Region (2021-2026) & (US$ Million) Table 65. Global AT1 Receptor Antagonists Revenue by Region (2027-2032) & (US$ Million) Table 66. Global AT1 Receptor Antagonists Revenue Market Share by Region (2021-2026) Table 67. Global AT1 Receptor Antagonists Revenue Market Share by Region (2027-2032) Table 68. Teva Pharmaceutical Company Information Table 69. Teva Pharmaceutical Business Overview Table 70. Teva Pharmaceutical AT1 Receptor Antagonists Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Teva Pharmaceutical AT1 Receptor Antagonists Product Portfolio Table 72. Teva Pharmaceutical Recent Development Table 73. Sanofi Company Information Table 74. Sanofi Business Overview Table 75. Sanofi AT1 Receptor Antagonists Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Sanofi AT1 Receptor Antagonists Product Portfolio Table 77. Sanofi Recent Development Table 78. Jhonson and Johnson Company Information Table 79. Jhonson and Johnson Business Overview Table 80. Jhonson and Johnson AT1 Receptor Antagonists Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Jhonson and Johnson AT1 Receptor Antagonists Product Portfolio Table 82. Jhonson and Johnson Recent Development Table 83. Novartis Company Information Table 84. Novartis Business Overview Table 85. Novartis AT1 Receptor Antagonists Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Novartis AT1 Receptor Antagonists Product Portfolio Table 87. Novartis Recent Development Table 88. Merck Company Information Table 89. Merck Business Overview Table 90. Merck AT1 Receptor Antagonists Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Merck AT1 Receptor Antagonists Product Portfolio Table 92. Merck Recent Development Table 93. Eli Lilly Company Information Table 94. Eli Lilly Business Overview Table 95. Eli Lilly AT1 Receptor Antagonists Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Eli Lilly AT1 Receptor Antagonists Product Portfolio Table 97. Eli Lilly Recent Development Table 98. Pfizer Company Information Table 99. Pfizer Business Overview Table 100. Pfizer AT1 Receptor Antagonists Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Pfizer AT1 Receptor Antagonists Product Portfolio Table 102. Pfizer Recent Development Table 103. GSK Company Information Table 104. GSK Business Overview Table 105. GSK AT1 Receptor Antagonists Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. GSK AT1 Receptor Antagonists Product Portfolio Table 107. GSK Recent Development Table 108. Bayer Company Information Table 109. Bayer Business Overview Table 110. Bayer AT1 Receptor Antagonists Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Bayer AT1 Receptor Antagonists Product Portfolio Table 112. Bayer Recent Development Table 113. Bristol-Myers Squibb Company Information Table 114. Bristol-Myers Squibb Business Overview Table 115. Bristol-Myers Squibb AT1 Receptor Antagonists Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Bristol-Myers Squibb AT1 Receptor Antagonists Product Portfolio Table 117. Bristol-Myers Squibb Recent Development Table 118. Astra Zeneca Company Information Table 119. Astra Zeneca Business Overview Table 120. Astra Zeneca AT1 Receptor Antagonists Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Astra Zeneca AT1 Receptor Antagonists Product Portfolio Table 122. Astra Zeneca Recent Development Table 123. Key Raw Materials Table 124. Raw Materials Key Suppliers Table 125. AT1 Receptor Antagonists Distributors List Table 126. AT1 Receptor Antagonists Customers List Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. AT1 Receptor Antagonists Product Image Figure 2. Global AT1 Receptor Antagonists Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global AT1 Receptor Antagonists Market Size (2021-2032) & (US$ Million) Figure 4. Global AT1 Receptor Antagonists Sales (2021-2032) & (k tons) Figure 5. Global AT1 Receptor Antagonists Average Price (US$/ton) & (2021-2032) Figure 6. Global Top 5 and 10 AT1 Receptor Antagonists Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Valsartan Image Figure 9. Telmisartan Image Figure 10. Losartan Image Figure 11. Irbesartan Image Figure 12. Olmesartan Image Figure 13. Azilsartan Image Figure 14. Global AT1 Receptor Antagonists Sales by Type (2021 VS 2025 VS 2032) & (k tons) Figure 15. Global AT1 Receptor Antagonists Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global AT1 Receptor Antagonists Sales Market Share by Type (2021-2032) Figure 17. Global AT1 Receptor Antagonists Revenue by Type (2021 VS 2025 VS 2032) & (k tons) Figure 18. Global AT1 Receptor Antagonists Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global AT1 Receptor Antagonists Revenue Market Share by Type (2021-2032) Figure 20. Cardiovascular Diseases Image Figure 21. Kidney Diseases Image Figure 22. Hypertension Image Figure 23. Other Image Figure 24. Global AT1 Receptor Antagonists Sales by Application (2021 VS 2025 VS 2032) & (k tons) Figure 25. Global AT1 Receptor Antagonists Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global AT1 Receptor Antagonists Sales Market Share by Application (2021-2032) Figure 27. Global AT1 Receptor Antagonists Revenue by Application (2021 VS 2025 VS 2032) & (k tons) Figure 28. Global AT1 Receptor Antagonists Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global AT1 Receptor Antagonists Revenue Market Share by Application (2021-2032) Figure 30. North America AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 31. North America AT1 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 32. U.S. AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 33. Canada AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 34. Mexico AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 35. Europe AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 36. Europe AT1 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 37. Germany AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 38. France AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 39. U.K. AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 40. Italy AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 41. Netherlands AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 42. Asia Pacific AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 43. Asia Pacific AT1 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 44. China AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 45. Japan AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 46. South Korea AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 47. Southeast Asia AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 48. India AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 49. Australia AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 50. South America, Middle East and Africa AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 51. South America, Middle East and Africa AT1 Receptor Antagonists Sales Market Share by Country (2021-2032) Figure 52. Brazil AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 53. South Africa AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 54. Saudi Arabia AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 55. Turkey AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 56. Argentina AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 57. UAE AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 58. Egypt AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 59. Chile AT1 Receptor Antagonists Sales and Growth Rate (2021-2032) & (k tons) Figure 60. Global AT1 Receptor Antagonists Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global AT1 Receptor Antagonists Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America AT1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Figure 63. North America AT1 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe AT1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Figure 65. Europe AT1 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific AT1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific AT1 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa AT1 Receptor Antagonists Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa AT1 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. AT1 Receptor Antagonists Value Chain Figure 71. Manufacturing Cost Structure Figure 72. AT1 Receptor Antagonists Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Valsartan
  • Telmisartan
  • Losartan
  • Irbesartan
  • Olmesartan
  • Azilsartan
Applications
  • Cardiovascular Diseases
  • Kidney Diseases
  • Hypertension
  • Other
Companies covered
  • Teva Pharmaceutical
  • Sanofi
  • Jhonson and Johnson
  • Novartis
  • Merck
  • Eli Lilly
  • Pfizer
  • GSK
  • Bayer
  • Bristol-Myers Squibb
  • Astra Zeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global AT1 Receptor Antagonists Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global AT1 Receptor Antagonists Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global AT1 Receptor Antagonists Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global AT1 Receptor Antagonists Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global AT1 Receptor Antagonists Market Dynamics
  1. 2.1 AT1 Receptor Antagonists Industry Trends
  2. 2.2 AT1 Receptor Antagonists Industry Drivers
  3. 2.3 AT1 Receptor Antagonists Industry Opportunities and Challenges
  4. 2.4 AT1 Receptor Antagonists Industry Restraints
3 AT1 Receptor Antagonists Market by Manufacturers
  1. 3.1 Global AT1 Receptor Antagonists Revenue by Manufacturers (2021-2026)
  2. 3.2 Global AT1 Receptor Antagonists Sales by Manufacturers (2021-2026)
  3. 3.3 Global AT1 Receptor Antagonists Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global AT1 Receptor Antagonists Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global AT1 Receptor Antagonists Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global AT1 Receptor Antagonists Manufacturers, Product Type & Application
  7. 3.7 Global AT1 Receptor Antagonists Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global AT1 Receptor Antagonists Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 AT1 Receptor Antagonists Players Market Share by Revenue in 2025
  11. 3.8.3 2025 AT1 Receptor Antagonists Tier 1, Tier 2, and Tier 3
4 AT1 Receptor Antagonists Market by Type
  1. 4.1 AT1 Receptor Antagonists Type Introduction
  2. 4.1.1 Valsartan
  3. 4.1.2 Telmisartan
  4. 4.1.3 Losartan
  5. 4.1.4 Irbesartan
  6. 4.1.5 Olmesartan
  7. 4.1.6 Azilsartan
  8. 4.2 Global AT1 Receptor Antagonists Sales by Type
  9. 4.2.1 Global AT1 Receptor Antagonists Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global AT1 Receptor Antagonists Sales by Type (2021-2032)
  11. 4.2.3 Global AT1 Receptor Antagonists Sales Market Share by Type (2021-2032)
  12. 4.3 Global AT1 Receptor Antagonists Revenue by Type
  13. 4.3.1 Global AT1 Receptor Antagonists Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global AT1 Receptor Antagonists Revenue by Type (2021-2032)
  15. 4.3.3 Global AT1 Receptor Antagonists Revenue Market Share by Type (2021-2032)
5 AT1 Receptor Antagonists Market by Application
  1. 5.1 AT1 Receptor Antagonists Application Introduction
  2. 5.1.1 Cardiovascular Diseases
  3. 5.1.2 Kidney Diseases
  4. 5.1.3 Hypertension
  5. 5.1.4 Other
  6. 5.2 Global AT1 Receptor Antagonists Sales by Application
  7. 5.2.1 Global AT1 Receptor Antagonists Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global AT1 Receptor Antagonists Sales by Application (2021-2032)
  9. 5.2.3 Global AT1 Receptor Antagonists Sales Market Share by Application (2021-2032)
  10. 5.3 Global AT1 Receptor Antagonists Revenue by Application
  11. 5.3.1 Global AT1 Receptor Antagonists Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global AT1 Receptor Antagonists Revenue by Application (2021-2032)
  13. 5.3.3 Global AT1 Receptor Antagonists Revenue Market Share by Application (2021-2032)
6 Global AT1 Receptor Antagonists Sales by Region
  1. 6.1 Global AT1 Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global AT1 Receptor Antagonists Sales by Region (2021-2032)
  3. 6.2.1 Global AT1 Receptor Antagonists Sales by Region (2021-2026)
  4. 6.2.2 Global AT1 Receptor Antagonists Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America AT1 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America AT1 Receptor Antagonists Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe AT1 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe AT1 Receptor Antagonists Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific AT1 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific AT1 Receptor Antagonists Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa AT1 Receptor Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa AT1 Receptor Antagonists Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global AT1 Receptor Antagonists Revenue by Region
  1. 7.1 Global AT1 Receptor Antagonists Revenue by Region
  2. 7.1.1 Global AT1 Receptor Antagonists Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global AT1 Receptor Antagonists Revenue by Region (2021-2026)
  4. 7.1.3 Global AT1 Receptor Antagonists Revenue by Region (2027-2032)
  5. 7.1.4 Global AT1 Receptor Antagonists Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America AT1 Receptor Antagonists Revenue (2021-2032)
  8. 7.2.2 North America AT1 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe AT1 Receptor Antagonists Revenue (2021-2032)
  11. 7.3.2 Europe AT1 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific AT1 Receptor Antagonists Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific AT1 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa AT1 Receptor Antagonists Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa AT1 Receptor Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical
  2. 8.1.1 Teva Pharmaceutical Company Information
  3. 8.1.2 Teva Pharmaceutical Business Overview
  4. 8.1.3 Teva Pharmaceutical AT1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical AT1 Receptor Antagonists Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi AT1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi AT1 Receptor Antagonists Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Jhonson and Johnson
  14. 8.3.1 Jhonson and Johnson Company Information
  15. 8.3.2 Jhonson and Johnson Business Overview
  16. 8.3.3 Jhonson and Johnson AT1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Jhonson and Johnson AT1 Receptor Antagonists Product Portfolio
  18. 8.3.5 Jhonson and Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis AT1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis AT1 Receptor Antagonists Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck AT1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck AT1 Receptor Antagonists Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Eli Lilly
  32. 8.6.1 Eli Lilly Company Information
  33. 8.6.2 Eli Lilly Business Overview
  34. 8.6.3 Eli Lilly AT1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly AT1 Receptor Antagonists Product Portfolio
  36. 8.6.5 Eli Lilly Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer AT1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer AT1 Receptor Antagonists Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 GSK
  44. 8.8.1 GSK Company Information
  45. 8.8.2 GSK Business Overview
  46. 8.8.3 GSK AT1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GSK AT1 Receptor Antagonists Product Portfolio
  48. 8.8.5 GSK Recent Developments
  49. 8.9 Bayer
  50. 8.9.1 Bayer Company Information
  51. 8.9.2 Bayer Business Overview
  52. 8.9.3 Bayer AT1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bayer AT1 Receptor Antagonists Product Portfolio
  54. 8.9.5 Bayer Recent Developments
  55. 8.10 Bristol-Myers Squibb
  56. 8.10.1 Bristol-Myers Squibb Company Information
  57. 8.10.2 Bristol-Myers Squibb Business Overview
  58. 8.10.3 Bristol-Myers Squibb AT1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Myers Squibb AT1 Receptor Antagonists Product Portfolio
  60. 8.10.5 Bristol-Myers Squibb Recent Developments
  61. 8.11 Astra Zeneca
  62. 8.11.1 Astra Zeneca Company Information
  63. 8.11.2 Astra Zeneca Business Overview
  64. 8.11.3 Astra Zeneca AT1 Receptor Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Astra Zeneca AT1 Receptor Antagonists Product Portfolio
  66. 8.11.5 Astra Zeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 AT1 Receptor Antagonists Value Chain Analysis
  2. 9.1.1 AT1 Receptor Antagonists Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 AT1 Receptor Antagonists Production Mode & Process
  6. 9.2 AT1 Receptor Antagonists Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 AT1 Receptor Antagonists Distributors
  9. 9.2.3 AT1 Receptor Antagonists Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst